Top

Published in:

01-02-2014 | Research Article

COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death

Authors: Maolin He, Zhe Wang, Jinmin Zhao, Yingbin Chen, Yang Wu

Published in: Tumor Biology | Issue 2/2014

Abstract

Osteosarcoma is a life-threatening malignancy that often occurs in teenagers. Collagen type I alpha 1 (COL1A1) polymorphism is reportedly associated with the occurrence of several human diseases. However, the relationship between COL1A1 and osteosarcoma occurrence remains unknown, and there is no report about the prevalence of COL1A1 in osteosarcoma. The purpose of this study is to investigate the associations of COL1A1 polymorphism with the susceptibility and survival of osteosarcoma. The relative risk to develop osteosarcomas and the overall survival associated to COL1A1 polymorphism were investigated in a homogeneous group of 189 osteosarcomas patients. Correlations with overall survival and hazard ratios (HR) were also analyzed. CT genotype and C allele of COL1A1 at rs1061970, and CG genotype and G allele of COL1A1 at rs2075559 are associated with decreased susceptibility to osteosarcoma in the Chinese population. CC genotype and C allele of COL1A1 at rs1061970 are associated with nonmetastasis in patients. CC genotype and CT genotype of COL1A1 at rs1061970 are associated with lower risk of death. Metastasis was found to be an independent prognostic factor for survival. This study provides the first evidence for the association between COL1A1 polymorphism and osteosarcoma risk in Chinese and shows that COL1A1 polymorphism at rs1061970 has a prognostic value for overall survival in osteosarcoma patients.

Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009;152:15–32. doi:10.1007/978-1-4419-0284-9_2.PubMedCrossRef

Fuchs B, Zhang K, Schabel A, Bolander ME, Sarkar G. Identification of twenty-two candidate markers for human osteogenic sarcoma. Gene. 2001;278(1–2):245–52.PubMedCrossRef

Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37(1):1–11.PubMedCrossRef

Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res. 1996;56(10):2434–9.PubMed

Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467–78. doi:10.1007/978-1-4419-0284-9_27.PubMedCrossRef

Foster L, Dall GF, Reid R, Wallace WH, Porter DE. Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br. 2007;89(9):1234–8. doi:10.1302/0301-620X.89B9.19255.PubMedCrossRef

Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact. 2002;2(6):549–51.PubMed

Prockop DJ. Mutations that alter the primary structure of type I collagen. The perils of a system for generating large structures by the principle of nucleated growth. J Biol Chem. 1990;265(26):15349–52.PubMed

Ertugay OC, Ata P, Kalaycik Ertugay C, Kaya KS, Tatlipinar A, Kulekci S. Association of COL1A1 polymorphism in Turkish patients with otosclerosis. Am J Otolaryngol. 2013. doi:10.1016/j.amjoto.2013.02.001.

10.

Inamori Y, Ota M, Inoko H, Okada E, Nishizaki R, Shiota T, et al. The COL1A1 gene and high myopia susceptibility in Japanese. Hum Genet. 2007;122(2):151–7. doi:10.1007/s00439-007-0388-1.PubMedCrossRef

11.

Zhao YP, Wang H, Fang M, Ji Q, Yang ZX, Gao CF. Study of the association between polymorphisms of the COL1A1 gene and HBV-related liver cirrhosis in Chinese patients. Dig Dis Sci. 2009;54(2):369–76. doi:10.1007/s10620-008-0340-9.PubMedCrossRef

12.

Kostik MM, Smirnov AM, Demin GS, Nuskina M, Scheplyagina LA, Larionova VI. Genetic polymorphisms of collagen type I alpha1 chain (COL1A1) gene increase the frequency of low bone mineral density in the subgroup of children with juvenile idiopathic arthritis. EPMA J. 2013;4(1):15. doi:10.1186/1878-5085-4-15.PubMedCentralPubMedCrossRef

13.

Tilkeridis C, Bei T, Garantziotis S, Stratakis CA. Association of a COL1A1 polymorphism with lumbar disc disease in young military recruits. J Med Genet. 2005;42(7):e44. doi:10.1136/jmg.2005.033225.PubMedCrossRef

14.

Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet. 2001;29(2):229–32. doi:10.1038/ng1001-229ng1001-229.PubMedCrossRef

15.

Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296(5576):2225–9. doi:10.1126/science.PubMedCrossRef

16.

Zhang K, Deng M, Chen T, Waterman MS, Sun F. A dynamic programming algorithm for haplotype block partitioning. Proc Natl Acad Sci U S A. 2002;99(11):7335–9. doi:10.1073/pnas.102186799.PubMedCentralPubMedCrossRef

17.

Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74(1):106–20. doi:10.1086/381000.PubMedCentralPubMedCrossRef

18.

Huang J, Lee C, Yu Q. A generalized log-rank test for interval-censored failure time data via multiple imputation. Stat Med. 2008;27(17):3217–26. doi:10.1002/sim.3211.PubMedCrossRef

19.

Ziegler A, Lange S, Bender R. Survival analysis: log rank test. Dtsch Med Wochenschr. 2007;132 Suppl 1:e39–41. doi:10.1055/s-2007-959040.PubMedCrossRef

20.

Provenzano F, D’Arrigo G, Zoccali C, Tripepi G. Cox regression analysis in epidemiological research. G Ital Nefrol. 2011;28(3):319–22.PubMed

21.

Seigel DG. Cox regression analysis in clinical research. Arch Ophthalmol. 1990;108(6):888–9.PubMedCrossRef

22.

Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–20.PubMed

23.

Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.PubMed

24.

Naumov VA, Generozov EV, Solovyov YN, Aliev MD, Kushlinsky NE. Association of FGFR3 and MDM2 gene nucleotide polymorphisms with bone tumors. Bull Exp Biol Med. 2012;153(6):869–73.PubMedCrossRef

25.

Hao T, Feng W, Zhang J, Sun YJ, Wang G. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients. Asian Pac J Cancer Prev. 2012;13(8):3821–4.PubMedCrossRef

26.

Liu Y, Lv B, He Z, Zhou Y, Han C, Shi G, et al. Lysyl oxidase polymorphisms and susceptibility to osteosarcoma. PLoS ONE. 2012;7(7):e41610. doi:10.1371/journal.pone.0041610.PubMedCentralPubMedCrossRef

27.

Caronia D, Patino-Garcia A, Perez-Martinez A, Pita G, Moreno LT, Zalacain-Diez M, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS ONE. 2011;6(10):e26091. doi:10.1371/journal.pone.0026091.PubMedCentralPubMedCrossRef

28.

Jin H, Stewart TL, Hof RV, Reid DM, Aspden RM, Ralston S. A rare haplotype in the upstream regulatory region of COL1A1 is associated with reduced bone quality and hip fracture. J Bone Miner Res. 2009;24(3):448–54. doi:10.1359/jbmr.081111.PubMedCrossRef

29.

Panagopoulos I, Mertens F, Lofvenberg R, Mandahl N. Fusion of the COL1A1 and USP6 genes in a benign bone tumor. Cancer Genet Cytogenet. 2008;180(1):70–3. doi:10.1016/j.cancergencyto.2007.09.017.PubMedCrossRef

30.

Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006;66(9):4662–71. doi:10.1158/0008-5472.CAN-05-2804.PubMedCrossRef

31.

Moro L, Arbini AA, Marra E, Greco M. Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation. J Biol Chem. 2005;280(23):22482–91. doi:10.1074/jbc.M414091200.PubMedCrossRef

32.

Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45(7):799–803. doi:10.1038/ng.2645ng.2645.PubMedCentralPubMedCrossRef

33.

Amin N, van Duijn CM, Aulchenko YS. A genomic background based method for association analysis in related individuals. PLoS ONE. 2007;2(12):e1274. doi:10.1371/journal.pone.0001274.PubMedCentralPubMedCrossRef

34.

Shi H, Bevier M, Johansson R, Enquist-Olsson K, Henriksson R, Hemminki K, et al. Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer. Breast Cancer Res Treat. 2012;131(3):1039–47. doi:10.1007/s10549-011-1826-2.PubMedCrossRef

35.

Bustamante M, Nogues X, Enjuanes A, Elosua R, Garcia-Giralt N, Perez-Edo L, et al. COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women. Osteoporos Int. 2007;18(2):235–43. doi:10.1007/s00198-006-0225-8.PubMedCrossRef

Title: COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death
Authors: Maolin He
Zhe Wang
Jinmin Zhao
Yingbin Chen
Yang Wu
Publication date: 01-02-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1172-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

RETRACTED ARTICLE: Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis

WW domain containing oxidoreductase induces apoptosis in gallbladder-derived malignant cell by upregulating expression of P73 and PUMA

A critical review on HE4 performance in endometrial cancer: where are we now?

Effect of the cytokine levels in serum on osteosarcoma

miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway

Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer